FDA Alerts

FDA Approves First Treatment for Photo-Toxic Reactions
The FDA approved a new therapy to increase pain-free light exposure in adult patients with a history of phototoxic reactions caused by erythropoietic protoporphyria.
FDA Approves New Treatment for Facial and Truncal Acne
The FDA recently approved a new topical retinoid for the treatment of acne on both the face and the trunk.
FDA Approves Expanded Indication of Topical Acne Treatment
The FDA approved the expanded indication of topical dapsone 7.5% gel for the treatment of acne vulgaris in patients aged 9 to 11 years.
FDA Approves Therapy for Oral Ulcers Associated with Rare Disease
The FDA approved a new treatment option for patients with oral ulcers associated with Behçet disease.
FDA Approves New Option for Chronic Rhinosinusitis With Nasal Polyps
The FDA has approved the first treatment option for chronic, inadequately controlled rhinosinusitis with nasal polyps.
FDA Approves New Psoriasis Treatment for Adolescents
The FDA approved a new foam treatment for adolescents with plaque psoriasis on the scalp and body.
FDA Approves Enbrel Biosimilar
The FDA has approved a second biosimilar to etanercept for the treatment of various autoimmune conditions.

FDA Approves Topical Therapy for Psoriasis
The FDA has approved a new topical therapy for the treatment of plaque psoriasis in adult patients.
FDA Approves New Therapy for Psoriasis
The FDA approved a new biologic for the treatment of moderate to severe plaque psoriasis.
FDA Approves Biologic for Adolescents with Eczema
The FDA approved dupiliumab for the treatment of moderate to severe atopic dermatitis in adolescents.
Back to Top